Psychedelics: The New Frontier of Mental Health?

The Essential Conversation ·
Featuring Christian Angermayer and Jeff Siegel

Published on: January 12th, 2022 • Duration: 57 minutes

With countless people suffering from anxiety and depression in the wake of the COVID-19 pandemic, could psychedelic drugs be poised to become a key treatment? Christian Angermayer, founder of Apeiron Investments, Atai Life Sciences, and COMPASS Pathways, lays out his vision for the future of the psychedelics sector, in which once-taboo substances like psilocybin are administered in clinical settings on a global scale. In a discussion with JLS Fund managing partner Jeff Siegel, the billionaire gives an inside look into some of the recent ups and downs experienced by Atai and COMPASS. He also explains his view on why Atai is currently undervalued and hints at some big things to come. Recorded on January 10, 2022.